Editorials

Funding PrEP for HIV prevention

BMJ 2016; 354 doi: http://dx.doi.org/10.1136/bmj.i3515 (Published 05 July 2016) Cite this as: BMJ 2016;354:i3515
  1. Jim McManus, director of public health1,
  2. Dominic Harrison, director of public health2
  1. 1Hertfordshire County Council, Hertford, UK
  2. 2Blackburn with Darwen Borough Council, Blackburn BB1 7DY, UK
  1. Correspondence to: D Harrison Dominic.Harrison{at}blackburn.gov.uk

Delays by NHS England will cost lives—it’s time to do the right thing

Despite overwhelming evidence that pre-exposure prophylaxis (PrEP) against HIV infection is largely safe, effective,1 2 3 4 and cost effective,4 5 6 7 NHS England has declined to make it available on the NHS, arguing that HIV prevention is the responsibility of local government.8

NHS England’s apparent appetite for legalistic cost shunting,9 and its argument that it does not have the legal power to commission PrEP,8 is regrettable. Such an approach confounds its advocacy of a health and care system integrated around the best outcomes for the citizen and perpetuates an incoherent national approach to HIV prevention.

PrEP has undoubtedly attracted some moral panic.10 11 Yet the clinical principle is not dissimilar to that of antimalarials, used to prevent malaria when travelling in at-risk environments. In population health, PrEP’s role is comparable to the function of vaccinations and immunisations, which NHS England …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe